Rufinamide probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).
Rufinamide may leads to higher adverse effects: diplopia compared with placebo (low certainty).
Rufinamide showed no clear difference in seizure freedom compared with placebo (moderate certainty).
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).
Rufinamide probably leads to higher adverse effects: fatigue compared with placebo (moderate certainty).
Rufinamide probably leads to higher adverse effects: headache compared with placebo (moderate certainty).
Rufinamide probably leads to higher adverse effects: somnolence compared with placebo (moderate certainty).
Rufinamide probably leads to higher adverse effects: nausea compared with placebo (moderate certainty).
Rufinamide may leads to higher adverse effects: vomiting compared with placebo (low certainty).